Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6489293

Title:Recombinant human erythropoietin with altered biological activity
Inventors:Sytkowski, Arthur J.; Arlington, MA, USA
Grodberg, Jennifer; Montreal, Canada
Summary:Described herein are methods of decreasing the growth and differentiation of red blood cell progenitor cells in an individual. Central to the invention is the discovery that DNA encoding modified, secretable erythropoietin proteins with the ability to regulate the growth and differentiation of red blood cell progenitors are different from the wildtype recombinant erythropoietin. Methods and materials disclosed herein include administration to an individual of an effective amount of a secretable human recombinant erythropoietin variant having decreased ability to stimulate the growth and differentiation of red blood cell progenitor cells relative to the same biological activity of wildtype erythropoietin. Such an erythropoietin variant with altered biological activity is described as having at least one amino acid residue at any one of the positions 102 to 109 in Domain 1 which differs from the amino acid residue present in the corresponding position of wildtype erythropoietin. Therapeutic applications in the treatment of hematologic conditions are included.
Abstract:
US Patent Website:Click Here for Full Text of Patent
Title Number:US6489293
Application Number:US2000000520118
Date Filed:06/03/2000
Date Published:03/12/2002
Assignee:Beth Israel Deaconess Medical Center, Boston, MA, USA


 
Copyright © 2007 The Institute for Cellular Medicine  6/13/2021